AstraZeneca (GB:AZN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AstraZeneca’s Imfinzi has received FDA approval as the first immunotherapy for limited-stage small cell lung cancer, showcasing a significant advance in treatment with a 27% reduction in mortality risk. The approval is based on the ADRIATIC Phase III trial results, marking a breakthrough in a disease known for its rapid progression and poor prognosis. This development underscores AstraZeneca’s commitment to improving survival rates and offering new hope to patients.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
